Elsevier eBooks, Год журнала: 2023, Номер unknown, С. 749 - 773
Опубликована: Янв. 1, 2023
Язык: Английский
Circulation, Год журнала: 2023, Номер 147(8)
Опубликована: Янв. 25, 2023
Background: The American Heart Association, in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, weight) factors (cholesterol, blood pressure, glucose control) that contribute health. Statistical Update presents latest data on a range major clinical circulatory disease conditions (including congenital rhythm disorders, subclinical atherosclerosis, coronary failure, valvular venous peripheral artery disease) associated outcomes quality care, procedures, economic costs). Methods: through its Epidemiology Prevention Statistics Committee, continuously monitors evaluates sources stroke United States provide current information available annual review published literature year before writing. 2023 is product full year’s worth effort 2022 by dedicated volunteer clinicians scientists, committed government professionals, Association staff members. strives further understand help heal problems inflicted structural racism, public crisis can significantly damage mental perpetuate disparities access education, income, housing, several other vital healthy lives. This edition includes additional COVID-19 (coronavirus 2019) publications, as well monitoring benefits population, an enhanced focus equity across key domains. Results: Each chapters focuses different topic statistics. Conclusions: represents critical resource for lay public, policymakers, media clinicians, care administrators, researchers, advocates, others seeking best these conditions.
Язык: Английский
Процитировано
4333
Journal of Hypertension, Год журнала: 2023, Номер 41(12), С. 1874 - 2071
Опубликована: Июнь 24, 2023
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos Kazuomi Kario (Japan), Vasilios Kotsis Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack Paolo Mulatero Dike B. Ojji (Nigeria), Sungha Park Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz Venkata Ram Ramiro Sanchez (Argentina), Markus Schlaich Alta Schutte Cristina Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios Bruno Trimarco Thomas Unger (The Netherlands), Bert-Jan van den Born Anna Vachulova Agostino Virdis Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton Jiri Widimsky (Czech Jacek Wolf Grégoire Wuerzner (Switzerland), Eugene Yang Yuqing Zhang (China).
Язык: Английский
Процитировано
1661
Circulation, Год журнала: 2024, Номер 149(8)
Опубликована: Янв. 24, 2024
BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, obesity) factors (cholesterol, blood pressure, glucose control, metabolic syndrome) that contribute health. AHA Disease Stroke Statistical Update presents latest data on a range major clinical circulatory disease conditions (including brain health, complications pregnancy, kidney congenital rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary cardiomyopathy, failure, valvular venous thromboembolism, peripheral artery disease) associated outcomes quality care, procedures, economic costs). METHODS: AHA, through its Epidemiology Prevention Statistics Committee, continuously monitors evaluates sources stroke United States globally provide current information available annual review published literature year before writing. 2024 is product full year’s worth effort 2023 by dedicated volunteer clinicians scientists, committed government professionals, staff members. strives further understand help heal problems inflicted structural racism, public crisis can significantly damage mental perpetuate disparities access education, income, housing, several other vital healthy lives. This edition includes additional global data, as well monitoring benefits population, an enhanced focus equity across key domains. RESULTS: Each chapters focuses different topic statistics. CONCLUSIONS: represents critical resource for lay public, policymakers, media clinicians, care administrators, researchers, advocates, others seeking best these conditions.
Язык: Английский
Процитировано
1025
Hypertension, Год журнала: 2022, Номер 80(1), С. 22 - 34
Опубликована: Окт. 5, 2022
Hypertension affects a significant proportion of the adult and aging population represents an important risk factor for vascular cognitive impairment late-life dementia. Chronic high blood pressure continuously challenges structural functional integrity cerebral vasculature, leading to microvascular rarefaction dysfunction, neurovascular uncoupling that typically impairs supply. disrupts blood-brain barrier integrity, promotes neuroinflammation, may contribute amyloid deposition Alzheimer pathology. The mechanisms underlying these harmful effects are still focus investigation, but studies in animal models have provided molecular cellular mechanistic insights. Remaining questions relate whether adequate treatment hypertension prevent deterioration function, threshold treatment, most effective antihypertensive drugs. Recent advances biology, advanced brain imaging, detection subtle behavioral phenotypes begun provide insights into critical issues. Importantly, parallel analysis parameters humans is feasible, making it possible foster translational advancements. In this review, we evaluation evidence available experimental examine progress made identify remaining gaps knowledge.
Язык: Английский
Процитировано
135
Hypertension, Год журнала: 2024, Номер 81(5), С. 991 - 1007
Опубликована: Март 1, 2024
Elevated blood pressure is a well-established risk factor for age-related cognitive decline. Long linked to impairment on vascular bases, increasing evidence suggests potential association of hypertension with the neurodegenerative pathology underlying Alzheimer disease. Hypertension well known disrupt structural and functional integrity cerebral vasculature. However, mechanisms by which these alterations lead brain damage, enhance pathology, promote remain be established. Furthermore, critical questions concerning whether lowering antihypertensive medications prevents have not been answered. Recent developments in neurovascular biology, imaging, epidemiology, as new clinical trials, provided insights into issues. In particular, basic findings link between dysfunction pathobiology neurodegeneration shed light overlap pathology. this review, we will examine progress made relationship and, after evaluation evidence, attempt identify remaining knowledge gaps future research directions that may advance our understanding one leading health challenges time.
Язык: Английский
Процитировано
37
Hypertension, Год журнала: 2022, Номер 79(10), С. 2159 - 2169
Опубликована: Сен. 7, 2022
Previous studies found that antihypertensive medications (AHMs) acting on the renin-angiotensin system had potential to reduce progression from mild cognitive impairment dementia. However, it remains unclear whether this association differs between ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers.We conducted a retrospective cohort study in Alzheimer's Disease Neuroimaging Initiative among 403 participants with hypertension at baseline. Information AHMs received during follow-up period, including blockers, inhibitors, beta-blockers, calcium channel diuretics, were self-reported. Cox proportional hazards models adjusted for confounders used time event analysis dementia as outcome.Of participants, mean (SD) age was 74.0 (7.3) years, 152 (37.7%) female, 158 (39.2%) progressed over median of 3.0 years. Angiotensin blockers associated lower risk compared (adjusted hazard ratio=0.45 [95% CI, 0.25-0.81]; P=0.023), other classes (beta-blockers, diuretics; ratio, 0.49 0.27-0.89]; P=0.037), none 0.31 0.16-0.58]; P=0.001).In patients impairment, AHMs. Our findings may have important implications clinical practice but still warrant further investigations larger prospective cohorts or trials.
Язык: Английский
Процитировано
33
Frontiers in Aging Neuroscience, Год журнала: 2023, Номер 15
Опубликована: Март 6, 2023
Recent studies on renin-angiotensin system (RAS) inhibitors have reported a reduced risk of Alzheimer's disease (AD). Nevertheless, the effect RAS inhibitor type and blood-brain barrier (BBB) permeability AD is still unknown.To assess effects based BBB investigate cumulative duration-response relationship.This was population-based retrospective cohort study using Korean Health Insurance Review Assessment database records from 2008 to 2019. The data patients diagnosed with ischemic heart between January 2009 June were identified for inclusion in analyses. Propensity score matching used balance users non-users. association use incident evaluated multivariate Cox proportional hazard regression model. results are presented adjusted ratios (aHRs) 95% confidence intervals (CIs).Among 57,420 matched individuals, 7,303 developed within follow-up period. While angiotensin-converting enzyme (ACEIs) not significantly associated risk, angiotensin II receptor blockers (ARBs) showed significant (aHR = 0.94; CI 0.90-0.99). Furthermore, BBB-crossing ARBs lower 0.83; 0.78-0.88) relationship. A higher dose or duration gradual decrease (P trend < 0.001). No ACEIs observed regardless permeability.Long-term development. finding may provide valuable insight into disease-modifying drug options preventing cardiovascular diseases.
Язык: Английский
Процитировано
22
medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown
Опубликована: Март 11, 2025
Angiotensin-II Receptor Blockers (ARBs) are commonly prescribed; however, their adverse events may prompt new drug prescription(s), known as prescribing cascades. We aimed to identify potential ARB-induced cascades using high-throughput sequence symmetry analysis. Using claims data from a national sample of Medicare beneficiaries (2011-2020), we identified ARB users aged ≥66 years with continuous enrollment ≥360 days before and ≥180 after initiation. screened for initiation 446 other (non-antihypertensive) 'marker' classes within ±90 initiation, generating ratios (SRs) reflecting proportions starting the marker class versus Adjusted SRs (aSRs) accounted trends over time, significant aSRs, calculated naturalistic number needed harm (NNTH); signals were reviewed by clinical experts plausibility. 320,663 initiators (mean ± SD age 76.0 7.2 years; 62.5% female; 91.5% hypertension). Of evaluated, 17 significant, three (18%) classified review. The strongest ranked lowest NNTH included benzodiazepine derivatives (NNTH 2130, 95% CI 1437-4525), adrenergics in combination anticholinergics, including triple combinations corticosteroids 2656, 1585-10074), antianemic preparations 9416, 6606-23784). highest aSR (aSR 1.7, 1.19-2.41), 1.18, 1.08-1.3), 1.12, 1.03-1.22). cascade reflected possibly under-recognized this cohort. These hypothesis-generating findings require further investigation determine extent impact these on patient outcomes.
Язык: Английский
Процитировано
1
Cardiovascular Research, Год журнала: 2025, Номер unknown
Опубликована: Фев. 13, 2025
Abstract As the population ages, anticipated rates of dementia worldwide are likely to increase dramatically, especially in low- and middle-income countries; thus, any opportunity modify risk is critical. Hypertension one factor that highly prevalent, consistently important for late-life brain health, which could represent a target prevention dementia. Furthermore, hypertension most significant modifiable stroke. This review will summarize existing literature linking with health more broadly, discuss potential mechanisms consider specific factors may impact not only relationship between but also importance treatment, including different associations over life course.
Язык: Английский
Процитировано
1
Journal of Neurorestoratology, Год журнала: 2022, Номер 10(3), С. 100008 - 100008
Опубликована: Июнь 28, 2022
Breakthroughs with rapid changes are the themes of development in Neurorestoratology this year. Given very difficult circumstances persistent COVID-19 pandemic, most colleagues have conducted meaningful research and obtained encouraging results, as described 2020 Yearbook Neurorestoratology. Neurorestorative progress during 2021 depicts recent findings on pathogenesis neurological diseases, neurorestorative mechanisms clinical therapeutic achievements. The risk factors Alzheimer's disease were parts prominent hot topics. Yet, it remains controversial whether β-amyloid accumulation tau protein deposition results of, or reasons for neurodegenerative processes. Neurogenesis is an important mechanism, however, questionable neural stem cells present adult humans brain. Thus, neurogenesis may not derive from endogenous humans. treatments areas efforts these therapies improving quality life patients diseases. There was major exploration cell-based injury. However, unfortunately several multi-center, double-blind observing-blind, placebo controlled, randomized trials mesenchymal stromal products failed to show positive ischemic stroke when employed sub-acute recovery phases there no appreciable differences compared controls. Excitingly, increased numbers investigations brain–computer interface (BCI) reported that showed benefits deficits. In pharmaceutical therapies, Aducanumab (Aduhelm) Sodium Oligomannate approved respectively by United States Food Drug Administration (USFDA) China National Medical Products (NMPA) treat mild-to-moderate disease. Although, decisions approve drugs highly contentious medical scientific community because contradictory other problems associated drug usage. We believe repeating low-level evidence studies negative scanty evidences control little significance. we strongly recommend conducting double-blind, promising innovative methods facilitate their possible translation.
Язык: Английский
Процитировано
28